Clinical trials: Patient Compliance
Obstructive Sleep Apnea
Nexus Compliance Study
Obstructive sleep apnoea (OSA) is characterised by a partial or complete collapse of the upper airway during sleep. The treatment of choice for OSA is Continuous Positive Airway Pressure (CPAP).
- Trial name
- NCT01013207
- Testing
- CPAP Pre Nexus (S9), Nexus (S9), CPAP Post Nexus (S9)
- Where
- Australia
- Volunteers
- 50 people
- Sponsor
- ResMed
Hypertension
Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients
This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.
- Trial name
- NCT00396656
- Testing
- Atenolol, Hydrochlorothiazide (HCTZ)), Valsartan
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 30 people
- Sponsor
- Novartis
Hypertension
Digital Health for Medication Adherence Among African Americans With Hypertension
The proposed Phase 1 project aims to develop and test Memento.HTN, an individually-tailored, culturally sensitive digital health intervention comprised of a provider platform and linked patient SMS (short message service) text…
- Trial name
- NCT05009004
- Testing
- text messages to support medication adherence
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Environment and Health Group, Inc.
Carcinoma, Non-Small-Cell Lung
Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance
The study will take place over a period of 27 months. The recruitment phase will last approximately 24 months and each patient will participate for approximately 3 months.
- Trial name
- NCT02483416
- Where
- 36 sites in France
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Premature Infants
Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA
Compliance to Synagis (palivizumab) is a key factor to obtain maximal protection against respiratory syncytial virus (RSV) infection as shown in the IMpact study.
- Trial name
- NCT01077271
- Where
- 45 sites in Austria
- Volunteers
- 124 people
- Sponsor
- Abbott
Patient Compliance
Actual Use Trial of Ibuprofen 400 mg
This is an open label, multicenter, 30 day study designed to mimic an OTC like environment in which subjects will use the product after making a purchase decision about ibuprofen 400 mg caplets based only on their reading of the…
- Trial name
- NCT02294019
- Testing
- Ibuprofen 400 mg caplet
- Where
- 25 sites in United States
- Volunteers
- 738 people
- Sponsor
- Pfizer
Medication Adherence, Glaucoma
A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications
Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective.
- Trial name
- NCT03506568
- Testing
- Devers Drop Device (D3) app
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Universal Adherence LLC
Epilepsy
Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening
Valproate is the first line therapy in primary generalized seizures. The applied drug contains sodium valproate in sustained release minitablets.
- Trial name
- NCT00870688
- Testing
- sodium valproate
- Volunteers
- 82 people
- Sponsor
- Desitin Arzneimittel GmbH
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Aim: To demonstrate the non-inferiority of the PRO-067 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- COMPLIANCE (NCT02801617)
- Testing
- PRO-067, GAAP Ofteno®
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Pain
Actual Use and Compliance Study Of Ibuprofen 600 Mg Immediate Release/Extended Release Tablets In At-Risk OTC Consumers
This will be an open-label, multicenter, 30-day, unsupervised AUS among targeted (at-risk) adult and adolescent consumers designed to mimic an OTC-like environment.
- Trial name
- NCT03722238
- Testing
- Ibuprofen 600 mg Immediate Release/Extended Release Caplet
- Where
- 27 sites in United States
- Volunteers
- 613 people, healthy volunteers welcome
- Sponsor
- Pfizer
Analgesia
Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet
A self-selection and actual use trial to evaluate the extent to which consumers will appropriately select and use the 600 mg immediate release/extended release caplets and comply with dosing instructions.
- Trial name
- NCT01789606
- Testing
- Ibuprofen 600 mg Immediate Release/Extended Release Caplet
- Where
- 18 sites in United States
- Volunteers
- 1,083 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatitis C, Chronic
ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)
This is a Phase 4, retrospective and observational, multicenter, national (Brazil), open, noncomparative, and nonrandomized study, which does not have visits. This study will be conducted in accordance to Good Clinical Practices.
- Trial name
- ATHENAS (NCT00856024)
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 902 people
- Sponsor
- Merck Sharp & Dohme LLC
Adolescent Idiopathic Scoliosis
Green Sun Medical Dynamic Scoliosis Brace
This is a pilot study to collect preliminary short-term data concerning the safety and performance of the Green Sun Dynamic brace in a sample of subjects with adolescent idiopathic scoliosis who are currently being treated with a…
- Trial name
- GSM (NCT03641469)
- Testing
- Green Sun Dynamic Brace
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Green Sun medical
Rheumatoid Arthritis
Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use
This is a prospective, single-arm, post marketing observational study in adult patients with active rheumatoid arthritis (RA) who are discontinuing treatment due to lack of efficacy, intolerance or to an incomplete response with…
- Trial name
- FALLA (NCT01083160)
- Where
- 12 sites in Mexico
- Volunteers
- 82 people
- Sponsor
- Abbott
Community-Acquired Pneumonia
Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia
To compare compliance between patients with CAP treated with Azithromycin SR 2.0 g single dose orally and those treated with Amoxiclav - 1000 mg twice daily 10 days for the empiric treatment of CAP in outpatient clinic practice.
- Trial name
- PROSTO (NCT01032694)
- Testing
- Azithromycin SR, Amoxiclav
- Volunteers
- 30 people
- Sponsor
- Pfizer
Ulcerative Colitis
A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting
This study evaluated the quality of life (QOL) and economic impact of adalimumab treatment in participants with ulcerative colitis (UC).
- Trial name
- InspirAda (NCT01550965)
- Testing
- Adalimumab
- Volunteers
- 463 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
History of Myocardial Infarction, Hypertriglyceridemia
A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy
A prospective observational program using digital technology tools to enhance patient adherence to Omacor therapy
- Trial name
- DIAPAsOn (NCT03415152)
- Testing
- Omacor (Omega-3-acid ethyl esters)
- Where
- 93 sites in Russia
- Volunteers
- 3,000 people
- Sponsor
- Abbott
Ulcerative Colitis
Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX mesalamine once daily.
- Trial name
- NCT00446849
- Testing
- MMX Mesalamine
- Where
- 62 sites in United States
- Volunteers
- 290 people
- Sponsor
- Shire
Post Menopausal Osteoporosis
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
This single arm, open label study will assess the efficacy and safety of and compliance to treatment with Bonviva/Boniva (ibandronate) in biphosphonate-naïve patients with post-menopausal osteoporosis.
- Trial name
- NCT01290094
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 2 sites in Bosnia and Herzegovina
- Volunteers
- 41 people
- Sponsor
- Hoffmann-La Roche
Human Immunodeficiency Virus Infection
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
Both twice-a-day (BID) and once-a-day (QD) dosing are approved in Europe for the protease inhibitor lopinavir/ritonavir (LPV/r; Kaletra®).
- Trial name
- QD-Kapital (NCT01383005)
- Where
- 20 sites in Spain
- Volunteers
- 97 people
- Sponsor
- AbbVie (prior sponsor, Abbott)